OptimizeRx Corporation
OptimizeRx Corporation (OPRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
oprx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for OptimizeRx Corporation (OPRX) measures how much investors pay for each dollar of the company's trailing earnings. OPRX's current PE ratio of 13.86x is calculated by dividing its stock price of $5.05 by its TTM earnings per share of $0.36. −98.4% discount vs 5Y avg 884.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%330.9x
MedianQ3 · 75%2830.2x
Max
At 13.86x, OPRX's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Healthcare Information Services · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
OptimizeRx CorporationYou OPRX | $95M | 13.86x | — | $0.36 |
 Definitive Healthcare Corp. DH | $89M | N/A | — | -$1.30 |
 Bright Minds Biosciences Inc. DRUG | $507M | N/A | — | -$1.78 |
 Nakamoto Inc. NAKA | $4.5B | N/A | — | -$4.60 |
 National Research Corporation NRC | $436M | 36.22x | — | $0.52 |
 RxSight, Inc. RXST | $205M | N/A | — | -$0.95 |
 Simulations Plus, Inc. SLP | $321M | N/A | — | -$3.22 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 44.33x | $0.28 | — | |
2024-12-31 FY2024 | — | $-1.10 | — | |
2023-12-31 FY2023 | — | $-1.03 | — | |
2022-12-31 FY2022 | — | $-0.64 | — | |
2021-12-31 FY2021 | 2830.18x | $0.02 | — | |
2020-12-31 FY2020 | — | $-0.15 | — | |
2019-12-31 FY2019 | — | $-0.23 | — | |
2018-12-31 FY2018 | 548.50x | $0.02 | — | |
2017-12-31 FY2017 | — | $-0.21 | — | |
2016-12-31 FY2016 | — | $-0.16 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for OptimizeRx Corporation (OPRX) measures how much investors pay for each dollar of the company's trailing earnings. OPRX's current PE ratio of 13.86x is calculated by dividing its stock price of $5.05 by its TTM earnings per share of $0.36.
Frequently asked questions
OPRX pe ratio · 6 questionsOPRX's current PE ratio is 13.86x as of 2026-06-08, based on a stock price of $5.05 and TTM EPS of $0.36. Data sourced from Financial Modeling Prep via OPRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · OptimizeRx Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08